Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
